US4776973A - Pyrimidine derivatives - Google Patents

Pyrimidine derivatives Download PDF

Info

Publication number
US4776973A
US4776973A US06/832,120 US83212086A US4776973A US 4776973 A US4776973 A US 4776973A US 83212086 A US83212086 A US 83212086A US 4776973 A US4776973 A US 4776973A
Authority
US
United States
Prior art keywords
ether
phenyl
trans
phe
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/832,120
Inventor
Klaus Bofinger
Michael Romer
Bernhard Scheuble
Georg Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Assigned to MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG reassignment MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BOFINGER, KLAUS, ROMER, MICHAEL, SCHEUBLE, BERNHARD, WEBER, GEORG
Application granted granted Critical
Publication of US4776973A publication Critical patent/US4776973A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/345—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing two nitrogen atoms
    • C09K19/3458—Uncondensed pyrimidines

Definitions

  • This invention relates to new pyrimidine derivatives. Similar compounds are known for example from German Offenlegungsschrift No. 3,040,632. However, the compounds sepcified there, unlike the present compounds, contain no pyrimidine-2,5-diyl groups.
  • R 1 and R 2 each independently are an alkyl group having 1 to 12 C atoms, in which one or two non-adjacent CH 2 groups can also be replaced by --O--, --CO--, --O--CO--, --CO--O-- or --CH ⁇ CH--, and one of the radicals R 1 and R 2 can also be H, F, Cl, Br or CN, Pyr is pyrimidine-2,5-diyl, A 1 and A 3 each independently are 1,4-cyclohexylene, unsubstituted 1,4-phenylene or 1,4-phenylene which is substituted by one or two F and/or Cl atoms and/or CH 3 and/or CN groups, A 2 is 1,4-phenylene which is unsubstituted or substituted by one or two F and/or Cl atoms and/or CH 3 and/or CN groups,
  • Z 1 is --CH 2 CH 2 --, --CH 2 O--, or --OCH 2 --
  • Z 2 is --CO--O--, --O--CO--, --CH 2 CH 2 --, --CH 2 O--, --O--CH 2 -- or a single bond, and
  • m 0 or 1.
  • Cy is a 1,4-cyclo-hexylene group and Phe is a 1,4-phenylene group which, if desired, can also be substituted by one or two F and/or Cl atoms and/or CH 3 and/or CN groups.
  • the compounds of the formula I can be used as components of liquid crystal phases, in particular for displays which are based on the principle of the twisted cell (TN displays), the guest host effect, the effect of the deformation of aligned phases or the effect of dynamic scattering.
  • TN displays twisted cell
  • the guest host effect the effect of the deformation of aligned phases or the effect of dynamic scattering.
  • the compounds of the formula I are highly suitable for use as components of liquid crystal phases.
  • they can be used to prepare stable liquid crystal phases for TN displays having high multiplex rates.
  • the compounds of the formula I have a wide range of uses. Depending on the choice of substituents, these compounds can be used as base materials of which liquid crystal phases are predominantly composed; but it is also possible to add compounds of the formula I to liquid crystal base materials of other classes of compounds, for example to reduce the dielectric and/or optical anisotropy of such a phase or to improve the elastic properties of such a phase.
  • the compounds of the formula I are also suitable for use as intermediates for preparing other substances which can be used as components of liquid crystal phases.
  • the compounds of the formula I are colorless in the pure state and form liquid crystal mesophases within a temperature range which is advantageously located for electro-optical use. They are very stable chemically, thermally and to light.
  • the invention accordingly provides the compounds of the formula I and a process for their preparation, characterised in that a compound which otherwise conforms to the formula I but contains in place of H atoms one or more reducible groups and/or additional C--C bonds is treated with a reducing agent, or, to prepare ethers of the formula I (in which R 1 and/or R 2 is an alkyl group in which one or two non-adjacent CH 2 groups are replaced O atoms and/or Z is a --OCH 2 -- or --CH 2 --O-- group), a corresponding hydroxy compound is etherified.
  • the invention also provides the use of the compounds of the formula I as components of liquid crystal phases.
  • the invention further provides liquid crystal phases containing at least one compound of the formula I, and liquid crystal display elements, in particular electrooptical display elements, which contain such phases.
  • R 1 , R 2 , A 1 , A 2 , A 3 , Z 1 , Z 2 and m have the specified meaning, unless otherwise stated.
  • the compounds of the formula I correspondingly include compounds of subformulae Ia and Ib (having three rings) and Ic and Id (having four rings):
  • the preferred compounds of subformula Ia include those of subformulae Iaa to Iac:
  • subformula Ib include those of subformulae Iba to Ibc:
  • Preferred compounds of subformulae Ic and Id are those of subformulae Ica to Icc:
  • R 1 and R 2 denote preferably alkyl and also alkoxy or oxaalkyl. Preference is also given to compounds of the formula I in which R 1 has one of the abovementioned preferred meanings (in particular alkyl) and R 2 is CN.
  • a 1 is preferably Phe, particularly preferably 1,4-phenylene.
  • a 2 is preferably unsubstituted 1,4-phenylene and also, if m is 0, preferably 2- or 3-fluoro-1,4-phenylene.
  • Z 1 is preferably --OCH 2 --.
  • m is preferably 0.
  • Z 2 is preferably a single bond or --O--CO--, particularly preferably --O--CO--.
  • a 3 is preferably Cy.
  • the alkyl radicals in the groups R 1 and/or R 2 can be straight-chain or branched. Preferably they are straight-chain, have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 C atoms and accordingly are preferably ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl or dodecyl, and also methyl.
  • Alkyl radicals R 1 and/or R 2 in which one ("alkoxy” or “oxaalkyl”) or two ("alkoxyalkoxy” or “dioxaalkyl") CH 2 groups are replaced by O atoms can be straight-chain or branched.
  • alkyl is preferably a straight-chain alkyl group having 2 to 10 C atoms and alkoxy a straight-chain alkoxy group having 2 to 12 C atoms. Preference is also given to compounds of the formulae I1 to I7 in which a 2-oxaalkyl group having 2 to 12 C atoms is present in place of alkoxy.
  • the abovementioned formulae include the two possible 2,5-positional isomers with respect to the pyrimidine-2,5-diyl group.
  • this group is attached to R 1 in the 5-position.
  • R 1 is a straight-chain alkyl group having 1 to 10 C atoms and R 2 is a straight-chain alkoxy, oxaalkyl or alkyl group having 2 to 15 C atoms, in particular having 5 to 12 C atoms.
  • R 1 or R 2 is an alkyl, alkoxy or oxaalkyl group having an optically active C atom.
  • the compounds of the formula I can be prepared by methods known per se, as described in the literature (for example in standard works such as Houben-Weyl, Methoden der Organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart) and using reaction conditions which are known and suitable for the reactions mentioned. In these reactions, it is also possible to take advantage of variants known per se which are not specifically mentioned here.
  • the starting materials can, if desired, also be formed in situ by not isolating them from the reaction mixture but immediately reacting them further to form compounds of the formula I.
  • the compounds of the formula I can be prepared by reducing a compound which otherwise conforms to the formula I but contains one or more reducible groups and/or C--C bonds in place of H atoms.
  • Reducible groups are preferably carbonyl groups, in particular keto groups, and also for example free or esterified hydroxyl groups or aromatically bonded halogen atoms.
  • Preferred starting materials for the reduction conform to the formula I but can contain, instead of a cyclohexane ring, a cyclohexene ring or cyclohexanone ring and/or, instead of a --CH 2 CH 2 -- group, a --CH ⁇ CH-- group and/or, in place of a --CH 2 -- group, a --CO-- group and/or, in place of an H atom, a free or functionally modified (for example in the form of its p-toluenesulphonate) OH group.
  • the reduction can be effected for example by catalytic hydrogenation at temperatures between 0° and about 200° and pressures between about 1 and 200 bar in an inert solvent, for example an alcohol such as methanol, ethanol or isopropanol, an ether such as tetrahydrofuran (THF) or dioxane, an ester such as ethyl acetate, a carboxylic acid such as acetic acid or a hydrocarbon such as cyclohexane.
  • an inert solvent for example an alcohol such as methanol, ethanol or isopropanol, an ether such as tetrahydrofuran (THF) or dioxane, an ester such as ethyl acetate, a carboxylic acid such as acetic acid or a hydrocarbon such as cyclohexane.
  • an inert solvent for example an alcohol such as methanol, ethanol or isopropanol, an ether such as tetra
  • Suitable catalysts are preferably noble metals such as Pt or Pd, which can be used in the form of oxides (for example PtO 2 , PdO), on a support (for example Pd on carbon, calcium carbonate or strontium carbonate) or in finely divided form.
  • Pt or Pd noble metals such as Pt or Pd, which can be used in the form of oxides (for example PtO 2 , PdO), on a support (for example Pd on carbon, calcium carbonate or strontium carbonate) or in finely divided form.
  • Ketones can also be reduced by the Clemmensen method (using zinc, amalgamated zinc or tin and hydrochloric acid, preferably in aqueous alcoholic solution or in heterogeneous phase with water/toluene at temperatures between about 80° and 120°) or by the Wolff-Kishner method (using hydrazine, preferably in the presence of alkali such as KOH or NaOH in a high-boiling solvent such as diethylene glycol or triethylene glycol at temperatures between about 100° to 200°) to the corresponding compounds of the formula I which contain alkyl groups and/or --CH 2 CH 2 -- bridges.
  • Clemmensen method using zinc, amalgamated zinc or tin and hydrochloric acid, preferably in aqueous alcoholic solution or in heterogeneous phase with water/toluene at temperatures between about 80° and 120°
  • the Wolff-Kishner method using hydrazine, preferably in the presence of alkali such as KOH or NaOH in
  • Ethers of the formula I are obtainable by etherification of corresponding hydroxy compounds, preferably corresponding phenols, the hydroxy compound preferably being first converted into a corresponding metal derivative, for example by treatment with NaH, NaNH 2 , NaOH, KOH, Na 2 CO 3 or K 2 CO 3 into the corresponding alkali metal alcoholate or alkali metal phenolate.
  • the liquid crystal phases according to the invention comprise 2 to 25, preferably 3 to 15, components, including at least one compound of the formula I.
  • the other components are preferably selected from the nematic or nematogenic substances, in particular the known substances, of the classes of azoxybenzenes, benzylideneanilines, biphenyls, terphenyls, phenyl or cyclohexyl benzoate, phenyl or cyclohexyl cyclohexane carboxylates, phenylcyclohexanes, cyclohexylbiphenyls, cyclohexylcyclohexanes, cyclohexylnaphthalenes, 1,4-biscyclohexylbenzenes, 4,4'-biscyclohexylbiphenyls, phenylpyrimidines, cyclohexylpyrimidines, phenyldioxanes, cyclohe
  • L and E are each a carbocyclic or heterocyclic ring system from the group comprising 1,4-disubstituted benzene and cyclohexane rings, 4,4'-disubstituted biphenyl, phenylcyclohexane and cyclohexylcyclohexane systems, 2,5-disubstituted pyrimidine and 1,3-dioxane rings, 2,6-disubstituted naphthalene, dihydronaphthalene, tetrahydronaphthalene, quinazoline and tetrahydroquinazoline
  • Y is halogen, preferably chlorine, or --CN
  • R' and R" are alkyl, alkoxy, alkanoyloxy or alkoxycarbonyloxy having up to 18, preferably up to 8, carbon atoms, or one of these radicals also is CN, NC, NO 2 , CF 3 , F, Cl or Br.
  • R' and R" are different from each other, one of these radicals usually being an alkyl or an alkoxy group.
  • R' and R" are also customary. Many such substances or mixtures thereof are commercially available. All these substances can be prepared by methods described in the literature.
  • the phases according to the invention contain about 0.1 to 99, preferably 10 to 95, % of one or more compounds of the formula I.
  • dielectrics according to the invention containing 0.1 to 40, preferably 0.5 to 29, % of one or more compounds of the formula I.
  • the dielectrics according to the invention are prepared in conventional manner. As a rule, the components are dissolved in one another, preferably at elevated temperature.
  • liquid crystal dielectrics according to the invention can be modified in such a way that they can be used in all previously disclosed types of liquid crystal display element.
  • Such additives are known to the person skilled in the art and are extensively described in the literature. It is possible for example to add conductive salts, preferably ethyldimethyldodecylammonium 4-hexyloxybenzoate, tetrabutylammonium tetraphenylboranate or complex salts of crown ethers (cf. for example I. Haller et al., Mol. Cryst. Liq. Cryst. Volume 24, pages 249-258 (1973)) to improve the conductivity, dichroic dyestuffs to prepare colored guest-host systems or substances to modify the dielectric anisotropy, the viscosity and/or the orientation of the nematic phases. Such substances are described for example in German Offenlegungsschriften Nos. 2,209,127, 2,240,864, 2,321,632, 2,338,281, 2,450,088, 2,637,430, 2,853,728 and 2,902,177.
  • Conventional working up means: addition of water, extraction with methylene chloride, separation, drying of the organic phase, evaporation and purification of the product by crystallization and/or chromatography.
  • a mixture of 0.04M of p-(5-n-heptalpyrimidin-2-yl)-benzyl bromide [obtainable from the corresponding benzyl alcohol, which is accessible by reaction of 2-n-heptylpropane-1,3-dialdehyde tetraethyl acetal with p-hydroxymethylbenzonitrile or the corresponding amidine by methods described in the literature], 0.04M of 4-cyano-3-fluorophenol, 0.2M of potassium carbonate and 150 ml of 2-butanone is boiled for 48 hours, is cooled down and is worked up in conventional manner. This gives p-(5-n-heptylpyrimidin-2-yl)-benzyl 4-cyano-3-fluorophenyl ether.
  • optically active compounds of the formula I are obtained by using the corresponding optically active starting materials.
  • 4-(5-n-nonylpyrimidin-2-yl)phenyl-[p-(2-methylbutoxycarbonyl)benzyl ether] is prepared from 2-p-hydroxyphenyl-5-n-nonylpyrimidine and p-bromomethyl(2-methylbutyl)benzoate (obtainable from p-bromomethylbenzoic acid and 2-methyl-1-butanol by esterification), mp 29°.
  • the following are prepared analogously:
  • a liquid crystal phase consisting of
  • 5% of 2-p-nonyloxyphenyl-5-heptylpyrimidine has a melting point of -10° and a clear point of 56°.
  • a liquid crystal phase consisting of
  • a liquid crystal phase consisting of
  • a liquid crystal phase consisting of
  • a liquid crystal phase is prepared from
  • a liquid crystal phase is prepared from

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

Pyrimidine derivatives of the formula I
R.sup.1 --Pry--A.sup.1 --Z.sup.1 --A.sup.2 -[Z.sup.2 --A.sup.3 ].sub.m
--R2 I
in which
R1 and R2 each are an alkyl group having 1 to 12 C atoms, in which one or two non-adjacent CH2 groups can also be replaced by --O--, --CO--, --O--CO--, --CO--O-- or --CH═CH--, and one of the radicals R1 and R2 are H, F, Cl, Br or CN,
Pyr is pyrimidine-2,5-diyl,
A1 and A3 each are 1,4-cyclohexylene, unsubstituted 1,4-phenylene or 1,4-phenylene which is substituted by one or two F and/or Cl atoms and/or CH3 and /or CN groups,
A2 is 1,4-phenylene which is unsubstituted or substituted by one or two F and/or Cl atoms and/or CH3 and/or CN groups,
Z1 is --CH2 CH2 --, --CH2 O--, or --OCH2 --
Z2 is --CO--O--, --O--CO--, --CH2 CH2 --, --CH2 O--, --O--CH2 -- or a single bond, and
m is 0 or 1,
are suitable for preparing liquid crystal phases having steep electro-optical characteristic curves.

Description

BACKGROUND OF THE INVENTION
This invention relates to new pyrimidine derivatives. Similar compounds are known for example from German Offenlegungsschrift No. 3,040,632. However, the compounds sepcified there, unlike the present compounds, contain no pyrimidine-2,5-diyl groups.
SUMMARY OF THE INVENTION
It is an object of this invention to provide new stable liquid crystal or mesogenic compounds which are suitable for use as components of liquid crystal phases.
These objects have been achieved by providing new pyrimidine derivatives of the formula I
R.sup.1 --Pyr--A.sup.1 --Z.sup.1 --A.sup.2 --[Z.sup.2 --A.sup.3 ].sub.m --R.sup.2                                                 I
in which
R1 and R2 each independently are an alkyl group having 1 to 12 C atoms, in which one or two non-adjacent CH2 groups can also be replaced by --O--, --CO--, --O--CO--, --CO--O-- or --CH═CH--, and one of the radicals R1 and R2 can also be H, F, Cl, Br or CN, Pyr is pyrimidine-2,5-diyl, A1 and A3 each independently are 1,4-cyclohexylene, unsubstituted 1,4-phenylene or 1,4-phenylene which is substituted by one or two F and/or Cl atoms and/or CH3 and/or CN groups, A2 is 1,4-phenylene which is unsubstituted or substituted by one or two F and/or Cl atoms and/or CH3 and/or CN groups,
Z1 is --CH2 CH2 --, --CH2 O--, or --OCH2 --
Z2 is --CO--O--, --O--CO--, --CH2 CH2 --, --CH2 O--, --O--CH2 -- or a single bond, and
m is 0 or 1.
For simplicity, hereinafter Cy is a 1,4-cyclo-hexylene group and Phe is a 1,4-phenylene group which, if desired, can also be substituted by one or two F and/or Cl atoms and/or CH3 and/or CN groups.
The compounds of the formula I, like similar compounds, can be used as components of liquid crystal phases, in particular for displays which are based on the principle of the twisted cell (TN displays), the guest host effect, the effect of the deformation of aligned phases or the effect of dynamic scattering.
DETAILED DESCRIPTION
It has been found that the compounds of the formula I are highly suitable for use as components of liquid crystal phases. In particular, they can be used to prepare stable liquid crystal phases for TN displays having high multiplex rates.
It was found, surprisingly, that on addition of compounds of the formula I to liquid crystal phases a considerable improvement in the slope of the characteristic curve of the mixture occurred, so that compounds of type I are to be regarded as particularly advantageously suitable substances for preparing liquid crystal mixtures having a steep characteristic curve.
They hence make it possible to develop highly multiplexible mixture with which a twisted cell can be operated in particular in the first Gooch-Tarry transmission minimum. The result is a very small dependence of the contrast on the angle of observation.
The provision of the compounds of the formula I also, very generally, considerably widens the range of liquid crystal compounds which, from various application viewpoints, are suitable for preparing liquid crystal mixtures.
The compounds of the formula I have a wide range of uses. Depending on the choice of substituents, these compounds can be used as base materials of which liquid crystal phases are predominantly composed; but it is also possible to add compounds of the formula I to liquid crystal base materials of other classes of compounds, for example to reduce the dielectric and/or optical anisotropy of such a phase or to improve the elastic properties of such a phase. The compounds of the formula I are also suitable for use as intermediates for preparing other substances which can be used as components of liquid crystal phases.
The compounds of the formula I are colorless in the pure state and form liquid crystal mesophases within a temperature range which is advantageously located for electro-optical use. They are very stable chemically, thermally and to light.
The invention accordingly provides the compounds of the formula I and a process for their preparation, characterised in that a compound which otherwise conforms to the formula I but contains in place of H atoms one or more reducible groups and/or additional C--C bonds is treated with a reducing agent, or, to prepare ethers of the formula I (in which R1 and/or R2 is an alkyl group in which one or two non-adjacent CH2 groups are replaced O atoms and/or Z is a --OCH2 -- or --CH2 --O-- group), a corresponding hydroxy compound is etherified.
The invention also provides the use of the compounds of the formula I as components of liquid crystal phases. The invention further provides liquid crystal phases containing at least one compound of the formula I, and liquid crystal display elements, in particular electrooptical display elements, which contain such phases.
Hereinbefore and hereinafter, R1, R2, A1, A2, A3, Z1, Z2 and m have the specified meaning, unless otherwise stated.
The compounds of the formula I correspondingly include compounds of subformulae Ia and Ib (having three rings) and Ic and Id (having four rings):
R.sup.1 --Pyr--Phe--Z.sup.1 --Phe--R.sup.2                 Ia
R.sup.1 --Pyr--Cy--Z.sup.1 --Phe--R.sup.2                  Ib
R.sup.1 --Pyr--Phe--Z.sup.1 --Phe--Z.sup.2 --A.sup.3 --R.sup.2 Ic
R.sup.1 --Pyr--Cy--Z.sup.1 --Phe--Z.sup.2 --A.sup.3 --R.sup.2 Id
Of these, those of subformulae Ia and Ic are preferred.
The preferred compounds of subformula Ia include those of subformulae Iaa to Iac:
R.sup.1 --Pyr--Phe--OCH.sub.2 --Phe--R.sup.2               Iaa
R.sup.1 --Pyr--Phe--CH.sub.2 CH.sub.2 --Phe--R.sup.2       Iab
R.sup.1 --Pyr--Phe--CH.sub.2 O--Phe--R.sup.2               Iac
Of these, those of subformula Iaa are particularly preferred.
The preferred compounds of subformula Ib include those of subformulae Iba to Ibc:
R.sup.1 --Pyr--Cy--OCH.sub.2 --Phe--R.sup.2                Iba
R.sup.1 --Pyr--Cy--CH.sub.2 CH.sub.2 --Phe--R.sup.2        Ibb
R.sup.1 --Pyr--Cy--CH.sub.2 O--Phe--R.sup.2                Ibc
Preferred compounds of subformulae Ic and Id are those of subformulae Ica to Icc:
R.sup.1 --Pyr--Phe--OCH.sub.2 --Phe--OCO--Cy--R.sup.2      Ica
R.sup.1 --Pyr--Phe--OCH.sub.2 --Phe--OCO--Phe--R.sup.2     Icb
R.sup.1 --Pyr--Phe--OCH.sub.2 --Phe--Cy--R.sup.2           Icc
Of these, those of subformula Ica are particularly preferred.
In the compounds of the formulae above and below, R1 and R2 denote preferably alkyl and also alkoxy or oxaalkyl. Preference is also given to compounds of the formula I in which R1 has one of the abovementioned preferred meanings (in particular alkyl) and R2 is CN.
A1 is preferably Phe, particularly preferably 1,4-phenylene.
A2 is preferably unsubstituted 1,4-phenylene and also, if m is 0, preferably 2- or 3-fluoro-1,4-phenylene.
Z1 is preferably --OCH2 --.
m is preferably 0.
Z2 is preferably a single bond or --O--CO--, particularly preferably --O--CO--.
A3 is preferably Cy.
The alkyl radicals in the groups R1 and/or R2 can be straight-chain or branched. Preferably they are straight-chain, have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 C atoms and accordingly are preferably ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl or dodecyl, and also methyl.
Alkyl radicals R1 and/or R2 in which one ("alkoxy" or "oxaalkyl") or two ("alkoxyalkoxy" or "dioxaalkyl") CH2 groups are replaced by O atoms can be straight-chain or branched. Preferably they are straight-chain, have 2, 3, 4, 5, 6 or 7 C atoms and accordingly are preferably ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, 2-oxapropyl (=methoxymethyl), 2-, 3- or 4-oxapentyl, 2-, 3-, 4- or 5-oxahexyl, 2-, 3-, 4-, 5- or 6-oxaheptyl, and also methoxy, octoxy, nonoxy, decoxy, 2-, 3-, 4-, 5-, 6-, 7-oxaoctyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-oxanonyl, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-oxadecyl, 1,3-dioxabutyl (=methoxymethoxy), 1,3-, 1,4- or 2,4-dioxapentyl, 1,3-, 1,4-, 1,5-, 2,4-, 2,5- or 3,5-dioxahexyl, 1,3-, 1,4-, 1,5-, 1,6-, 2,4-, 2,5-, 2,6-, 3,5-, 3,6- or 4,6-dioxaheptyl.
Compounds of the formula I and of the preceding and following subformulae having branched wing-groups R1 and R2 can occasionally be of importance because of higher solubility in the customary liquid crystal base materials, but in particular for use as chiral dopants when they are optically active. Branched groups of this kind generally contain no more than one chain branching. Preferred branched radicals R1 are isopropyl, 2-butyl (=1-methylpropyl), isobutyl (=2-methylpropyl), 2-methylbutyl, sopentyl (=3-methylbutyl), 2-methylpentyl, 3-methylipentyl, 2-ethylhexyl, 2-propylpentyl, 2-octyl, isopropoxy, 2-methylpropoxy, 2-methylbutoxy, 3-methylbutoxy, 2-methylpentoxy, 3-methylpentoxy, 2-ethylhexoxy, 1-methylhexoxy, 1-methylheptoxy, 2-oxa-3-methylbutyl, 3-oxa-4-methylpentyl, 2-octyloxy.
Of the compounds of the formula I, preference is given to those of the preceding and following subformulae in which at least one of the radicals contained therein has one of the indicated preferred meanings. Particularly preferred smaller groups of compounds are those of the ormulae I1 to I7:
Alkyl--Pyr--Phe--OCH.sub.2 --Phe--alkyl                    I1
Alkyl--Pyr--Phe--OCH.sub.2 --Phe--alkoxy                   I2
Alkyl--Pyr--Phe--OCH.sub.2 --Phe--CN                       I3
Alkyl--Pyr--Phe--OCH.sub.2 --Phe--OCO--Cy--alkyl           I4
Alkyl--Pyr--Phe--OCH.sub.2 --Phe--OCO--Phe--alkyl          I5
Alkyl--Pyr--Phe--OCH.sub.2 --Phe--OCO--Phe--alkoxy         I6
Alkyl--Pyr--Phe--OCH.sub.2 --Phe--Cy--alkyl                I7
In the above formulae I1 to I7, alkyl is preferably a straight-chain alkyl group having 2 to 10 C atoms and alkoxy a straight-chain alkoxy group having 2 to 12 C atoms. Preference is also given to compounds of the formulae I1 to I7 in which a 2-oxaalkyl group having 2 to 12 C atoms is present in place of alkoxy.
Of compounds of the formula I, preference is given to those stereoisomers in which the cyclohexane rings are trans-1,4-disubstituted.
The abovementioned formulae include the two possible 2,5-positional isomers with respect to the pyrimidine-2,5-diyl group. Preferably this group is attached to R1 in the 5-position.
Particular preference is given to compounds of the formula I and of the preceding subformulae in which R1 is a straight-chain alkyl group having 1 to 10 C atoms and R2 is a straight-chain alkoxy, oxaalkyl or alkyl group having 2 to 15 C atoms, in particular having 5 to 12 C atoms.
Particular preference is given further to compounds of the formula and of the preceding subformulae in which R1 or R2 is an alkyl, alkoxy or oxaalkyl group having an optically active C atom.
The compounds of the formula I can be prepared by methods known per se, as described in the literature (for example in standard works such as Houben-Weyl, Methoden der Organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart) and using reaction conditions which are known and suitable for the reactions mentioned. In these reactions, it is also possible to take advantage of variants known per se which are not specifically mentioned here.
The person skilled in the art can, by using routine methods, find appropriate methods of synthesis in the state of he art (for example German Offenlegungsschriften Nos. 2,344,732, 2,450,088, 2,429,093, 2,502,904, 2,636,684, 2,701,591 and 2,752,957 concerning compounds having 1,4-cyclohexylene and 1,4-phenylene groups and German Offenlegungsschrift No. 3,201,721 concerning compounds having --CH2 CH2 -- bridge members).
The starting materials can, if desired, also be formed in situ by not isolating them from the reaction mixture but immediately reacting them further to form compounds of the formula I.
For instance, the compounds of the formula I can be prepared by reducing a compound which otherwise conforms to the formula I but contains one or more reducible groups and/or C--C bonds in place of H atoms.
Reducible groups are preferably carbonyl groups, in particular keto groups, and also for example free or esterified hydroxyl groups or aromatically bonded halogen atoms. Preferred starting materials for the reduction conform to the formula I but can contain, instead of a cyclohexane ring, a cyclohexene ring or cyclohexanone ring and/or, instead of a --CH2 CH2 -- group, a --CH═CH-- group and/or, in place of a --CH2 -- group, a --CO-- group and/or, in place of an H atom, a free or functionally modified (for example in the form of its p-toluenesulphonate) OH group.
The reduction can be effected for example by catalytic hydrogenation at temperatures between 0° and about 200° and pressures between about 1 and 200 bar in an inert solvent, for example an alcohol such as methanol, ethanol or isopropanol, an ether such as tetrahydrofuran (THF) or dioxane, an ester such as ethyl acetate, a carboxylic acid such as acetic acid or a hydrocarbon such as cyclohexane. Suitable catalysts are preferably noble metals such as Pt or Pd, which can be used in the form of oxides (for example PtO2, PdO), on a support (for example Pd on carbon, calcium carbonate or strontium carbonate) or in finely divided form.
Ketones can also be reduced by the Clemmensen method (using zinc, amalgamated zinc or tin and hydrochloric acid, preferably in aqueous alcoholic solution or in heterogeneous phase with water/toluene at temperatures between about 80° and 120°) or by the Wolff-Kishner method (using hydrazine, preferably in the presence of alkali such as KOH or NaOH in a high-boiling solvent such as diethylene glycol or triethylene glycol at temperatures between about 100° to 200°) to the corresponding compounds of the formula I which contain alkyl groups and/or --CH2 CH2 -- bridges.
Ethers of the formula I (in which R1 and/or R2 is an alkyl group in which one or two CH2 groups are replaced by O atoms and/or in which Z1 and/or in which Z2 is a --OCH2 -- or a CH2 O-- group) are obtainable by etherification of corresponding hydroxy compounds, preferably corresponding phenols, the hydroxy compound preferably being first converted into a corresponding metal derivative, for example by treatment with NaH, NaNH2, NaOH, KOH, Na2 CO3 or K2 CO3 into the corresponding alkali metal alcoholate or alkali metal phenolate. The latter can then be reacted with the corresponding alkyl halide, alkyl sulphonate or dialkyl sulphate, preferably in an inert solvent such as acetone, 1,2-dimethoxyethane, DMF or dimethyl sulphoxide or in an excess of aqueous or aqueous alcoholic NaOH or KOH at temperatures between about 20° and 100°. Compounds of the formula I having an optically active R1 or R2 can be synthesized according to the above described methods by using the respective optically active starting materials.
The liquid crystal phases according to the invention comprise 2 to 25, preferably 3 to 15, components, including at least one compound of the formula I. The other components are preferably selected from the nematic or nematogenic substances, in particular the known substances, of the classes of azoxybenzenes, benzylideneanilines, biphenyls, terphenyls, phenyl or cyclohexyl benzoate, phenyl or cyclohexyl cyclohexane carboxylates, phenylcyclohexanes, cyclohexylbiphenyls, cyclohexylcyclohexanes, cyclohexylnaphthalenes, 1,4-biscyclohexylbenzenes, 4,4'-biscyclohexylbiphenyls, phenylpyrimidines, cyclohexylpyrimidines, phenyldioxanes, cyclohexyldioxanes, phenyl- or cyclohexyl-1,3-dithianes, 1,2-biscyclohexylethanes, 1,2-bisphenylethanes, 1-phenyl-2-cyclohexylethanes, stilbenes which may be halogenated, benzyl phenyl ethers, tolanes and substituted cinnamic acids.
The most important compounds which come into consideration for use as components of such liquid crystal phases can be characterized by the formula II
R'--L--G--E--R"                                            II
in which L and E are each a carbocyclic or heterocyclic ring system from the group comprising 1,4-disubstituted benzene and cyclohexane rings, 4,4'-disubstituted biphenyl, phenylcyclohexane and cyclohexylcyclohexane systems, 2,5-disubstituted pyrimidine and 1,3-dioxane rings, 2,6-disubstituted naphthalene, dihydronaphthalene, tetrahydronaphthalene, quinazoline and tetrahydroquinazoline
______________________________________                                    
--CH═CH--    --N(O)═--                                            
--CH═CY--    --CH═N(O)--                                          
--C.tbd.C--      --CH.sub.2 --CH.sub.2 --                                 
--CO--O--        --CH.sub.2 --O--                                         
--CO--S--        --CH.sub.2 --S--                                         
--CH═N--     --COO--Phe--COO--                                        
______________________________________
or a C--C single bond, Y is halogen, preferably chlorine, or --CN, and R' and R" are alkyl, alkoxy, alkanoyloxy or alkoxycarbonyloxy having up to 18, preferably up to 8, carbon atoms, or one of these radicals also is CN, NC, NO2, CF3, F, Cl or Br.
In most of these compounds, R' and R" are different from each other, one of these radicals usually being an alkyl or an alkoxy group. However, other variants on the proposed substituents are also customary. Many such substances or mixtures thereof are commercially available. All these substances can be prepared by methods described in the literature.
The phases according to the invention contain about 0.1 to 99, preferably 10 to 95, % of one or more compounds of the formula I.
Furthermore, preference is given to dielectrics according to the invention containing 0.1 to 40, preferably 0.5 to 29, % of one or more compounds of the formula I.
The dielectrics according to the invention are prepared in conventional manner. As a rule, the components are dissolved in one another, preferably at elevated temperature.
By means of suitable additives, the liquid crystal dielectrics according to the invention can be modified in such a way that they can be used in all previously disclosed types of liquid crystal display element.
Such additives are known to the person skilled in the art and are extensively described in the literature. It is possible for example to add conductive salts, preferably ethyldimethyldodecylammonium 4-hexyloxybenzoate, tetrabutylammonium tetraphenylboranate or complex salts of crown ethers (cf. for example I. Haller et al., Mol. Cryst. Liq. Cryst. Volume 24, pages 249-258 (1973)) to improve the conductivity, dichroic dyestuffs to prepare colored guest-host systems or substances to modify the dielectric anisotropy, the viscosity and/or the orientation of the nematic phases. Such substances are described for example in German Offenlegungsschriften Nos. 2,209,127, 2,240,864, 2,321,632, 2,338,281, 2,450,088, 2,637,430, 2,853,728 and 2,902,177.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. In the preceding text and the following examples, all temperatures are set forth uncorrected in degrees Celsius and all parts and percentages are by weight, unless otherwise indicated.
mp=melting point, cp=clear point.
"Conventional working up" means: addition of water, extraction with methylene chloride, separation, drying of the organic phase, evaporation and purification of the product by crystallization and/or chromatography.
EXAMPLE 1
A mixture of 10.2 g of 2-p-hydroxyphenyl-5-n-hexylpyrimidine, 8.6 g of p-n-propylbenzyl bromide, 8.6 g of potassium carbonate and 50 ml of dimethylformamide are heated at 90° for 10 hours. Conventional working up gives 4-(5-n-hexylpyrimidin-2-yl)-phenyl p-n-propylbenzyl ether.
The following are prepared analogously:
4-(5-Hexylpyrimidin-2-yl)-phenyl p-methylbenzyl ether
4-(5-Hexylpyrimidin-2-yl)-phenyl p-ethylbenzyl ether
4-(5-Hexylpyrimidin-2-yl)-phenyl p-butylbenzyl ether
4-(5-Hexylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether
mp 72°, cp 104°, S/N 65°, Δε=+1.0
4-(5-Hexylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether
mp 61°, cp 100.8°, S/N 76°, Δη=0.19
4-(5-Hexylpyrimidin-2-yl)-phenyl p-heptylbenzyl ether
4-(5-Hexylpyrimidin-2-yl)-phenyl p-octylbenzyl ether
4-(5-Hexylpyrimidin-2-yl)-phenyl p-nonylbenzyl ether
4-(5-Hexylpyrimidin-2-yl)-phenyl p-decylbenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-methylbenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-ethylbenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-propylbenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-butylbenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether
mp 76°, cp 109°, S/N 86°, Δε=+1.0
4-(5-Heptylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether
mp 48°, cp 107°, S/N 92°, Δη=0.19
4-(5-Heptylpyrimidin-2-yl)-phenyl p-heptylbenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-octylbenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-nonylbenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-decylbenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-cyanobenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-methoxybenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-ethoxybenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-butoxybenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-hexoxybenzyl ether
4-(5-Heptylpyrimidin-2-yl)-phenyl p-octoxybenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-methoxybenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-ethylbenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-propylbenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-butylbenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-heptylbenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-octylbenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-nonylbenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-decylbenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-cyanobenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-methoxybenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-ethoxybenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-butoxybenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-hexoxybenzyl ether
4-(5-Octylpyrimidin-2-yl)-phenyl p-octoxybenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-methylbenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-ethylbenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-propylbenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-butylbenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether
mp 52°, cp 113°, S/N 107°, Δε=+0.9
4-(5-Nonylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether
mp 66°, cp 110°, S/N 109°, Δη=0.18
4-(5-Nonylpyrimidin-2-yl)-phenyl p-heptylbenzyl ether, mp 51°, cp 112°
4-(5-Nonylpyrimidin-2-yl)-phenyl p-octylbenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-nonylbenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-decylbenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-cyanobenzyl ether, mp 105°, cp 168°
4-(5-Nonylpyrimidin-2-yl)-phenyl p-methoxybenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-ethoxybenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-butoxybenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-hexoxybenzyl ether
4-(5-Nonylpyrimidin-2-yl)-phenyl p-octoxybenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-methoxybenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-ethylbenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-propylbenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-butylbenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-heptylbenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-octylbenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-nonylbenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-decylbenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-cyanobenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-methoxybenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-ethoxybenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-butoxybenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-hexoxybenzyl ether
4-(5-Decylpyrimidin-2-yl)-phenyl p-octoxybenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-methylbenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-ethylbenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-propylbenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-butylbenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-heptylbenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-octylbenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-nonylbenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-decylbenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-cyanobenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-methoxybenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-ethoxybenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-butoxybenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-hexoxybenzyl ether
4-(5-Pentylpyrimidin-2-yl)-phenyl p-octoxybenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-methylbenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-ethylbenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-propylbenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-butylbenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-heptylbenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-octylbenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-nonylbenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-decylbenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-cyanobenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-methoxybenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-ethoxybenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-butoxybenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-hexoxybenzyl ether
4-(5-Butylpyrimidin-2-yl)-phenyl p-octoxybenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-methylbenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-ethylbenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-propylbenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-butylbenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-heptylbenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-octylbenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-nonylbenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-decylbenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-cyanobenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-methoxybenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-ethoxybenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-butoxybenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-hexoxybenzyl ether
4-(5-Propylpyrimidin-2-yl)-phenyl p-octoxybenzyl ether
EXAMPLE 2
To a mixture of 17.8 g of p-n-hexylphenol and 37 g of trans-4-trans-(5-n-hexylpyrimidin-2-yl)-cyclohexylmethanol mesylate [obtainable from the corresponding alcohol which is accessible by reaction of 2-n-hexylpropane-1,3-dialdehyde tetraethyl acetal with trans-4-cyanocyclohexylmethanol or the corresponding amidine by methods described in the literature] in 200 ml of toluene are added 5 g of tetrabutylammonium hydrogen sulphate and 20 ml of 50% NaOH, the mixture is heated with stirring at 70° for three hours and is worked up conventionally, which gives trans-4-(5-n-hexylpyrimidin-2-yl)-cyclohexylmethyl p-n-hexylphenyl ether.
The following are prepared analogously:
trans-4-(5-Hexylpyrimidin-2-yl)-cyclohexylmethyl p-propylphenyl ether
trans-4-(5-Hexylpyrimidin-2-yl)-cyclohexylmethyl p-butylphenyl ether
trans-4-(5-Hexylpyrimidin-2-yl)-cyclohexylmethyl p-pentylphenyl ether
trans-4-(5-Hexylpyrimidin-2-yl)-cyclohexylmethyl p-heptylphenyl ether
trans-4-(5-Hexylpyrimidin-2-yl)-cyclohexylmethyl p-nonylphenyl ether
trans-4-(5-Hexylpyrimidin-2-yl)-cyclohexylmethyl p-decylphenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl p-propylphenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl p-butylphenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl p-pentylphenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl p-hexylphenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl p-heptylphenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl p-octylphenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl p-nonylphenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl p-decylphenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl
p-dodecylphenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl p-cyanophenyl ether
trans-4-(5-Pentylpyrimidin-2-yl)-cyclohexylmethyl p-cyano-m-fluorophenyl ether
trans-4-(5-Heptylpyrimidin-2-yl)-cyclohexylmethyl p-propylphenyl ether
trans-4-(5-Heptylpyrimidin-2-yl)-cyclohexylmethyl p-butylphenyl ether
trans-4-(5-Heptylpyrimidin-2-yl)-cyclohexylmethyl p-pentylphenyl ether
trans-4-(5-Heptylpyrimidin-2-yl)-cyclohexylmethyl p-hexylphenyl ether
trans-4-(5-Heptylpyrimidin-2-yl)-cyclohexylmethyl p-heptylphenyl ether
trans-4-(5-Heptylyrimidin-2-yl)-cyclohexylmethyl p-octylphenyl ether
trans-4-(5-Heptylpyrimidin-2-yl)-cyclohexylmethyl p-nonylphenyl ether
trans-4-(5-Heptylpyrimidin-2-yl)-cyclohexylmethyl p-decylphenyl ether
trans-4-(5-Heptylpyrimidin-2-yl)-cyclohexylmethyl p-dodecylphenyl ether
trans-4-(5-Heptylpyrimidin-2-yl)-cyclohexylmethyl p-cyanophenyl ether
trans-4-(5-Heptylpyrimidin-2-yl)-cyclohexylmethyl p-cyano-m-fluorophenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-propylphenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-butylphenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-pentylphenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-hexylphenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-heptylphenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-octylphenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-nonylphenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-decylphenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-dodecylphenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-cyanophenyl ether
trans-4-(5-Nonylpyrimidin-2-yl)-cyclohexylmethyl p-cyano-m-fluorophenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-propylphenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-butylphenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-pentylphenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-hexylphenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-heptylphenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-octylphenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-nonylphenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-decylphenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-dodecylphenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-cyanophenyl ether
trans-4-(5-Decylpyrimidin-2-yl)-cyclohexylmethyl p-cyano-m-fluorophenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl p-propylphenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl p-butylphenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl p-pentylphenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl
p-hexylphenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl p-heptylphenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl p-octylphenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl p-nonylphenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl p-decylphenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl p-dodecylphenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl p-cyanophenyl ether
trans-4-(5-Dodecylpyrimidin-2-yl)-cyclohexylmethyl p-cyano-m-fluorophenyl ether
EXAMPLE 3
A mixture of 0.04M of p-(5-n-heptalpyrimidin-2-yl)-benzyl bromide [obtainable from the corresponding benzyl alcohol, which is accessible by reaction of 2-n-heptylpropane-1,3-dialdehyde tetraethyl acetal with p-hydroxymethylbenzonitrile or the corresponding amidine by methods described in the literature], 0.04M of 4-cyano-3-fluorophenol, 0.2M of potassium carbonate and 150 ml of 2-butanone is boiled for 48 hours, is cooled down and is worked up in conventional manner. This gives p-(5-n-heptylpyrimidin-2-yl)-benzyl 4-cyano-3-fluorophenyl ether.
The following are prepared analogously:
p-(5-Propylpyrimidin-2-yl)-benzyl 4-cyano-3-fluorophenyl ether
p-(5-Butylpyrimidin-2-yl)-benzyl 4-cyano-3-fluorophenyl ether
p-(5-Pentylpyrimidin-2-yl)-benzyl 4-cyano-3-fluorophenyl ether
p-(5-Hexylpyrimidin-2-yl)-benzyl 4-cyano-3-fluorophenyl ether
p-(5-Octylpyrimidin-2-yl)-benzyl 4-cyano-3-fluorophenyl ether
p-(5-Nonylpyrimidin-2-yl)-benzyl 4-cyano-3-fluorophenyl ether
p-(5-Decylpyrimidin-2-yl)-benzyl 4-cyano-3-fluorophenyl ether
p-(5-Dodecylpyrimidin-2-yl)-benzyl 4-cyano-3-fluorophenyl ether
EXAMPLE 4
According to the example 1 optically active compounds of the formula I are obtained by using the corresponding optically active starting materials.
A mixture of 11.9 g 2-p-hydroxyphenyl-5-n-nonylpyrimidine, 10.2 g p-(2-methylbutoxy)-benzylbromide (obtainable from 4-hydroxybenzaldehyde and 2-methylbutylmesylate in the presence of potassium carbonate in dimethylformamide, subsequently reduction of the benzaldehyde to the corresponding benzyl-alcohol and conversion with PBr3 to the corresponding benzylbromide), 8.6 g of potassium carbonate and 50 ml of dimethylformamide are heated at 90° for 10 hours. Conventional working up gives 4-(5-n-nonylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxy)benzylether], S-Ch 103°, Ch-I 105°.
The following are prepared analogously:
4-(5-n-Hexylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxy)benzyl ether]
4-(5-n-Heptylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxy)benzyl ether]
4-(5-n-Octylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxy)benzyl ether]
4-(5-n-Decylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxy)benzyl ether]
4-(5-n-Pentylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxy)benzyl ether]
4-(5-n-Butylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxy)benzyl ether]
4-(5-n-Propylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxy)benzyl ether]
EXAMPLE 5
According to the example 4 4-(5-n-nonylpyrimidin-2-yl)phenyl-[p-(2-methylbutoxycarbonyl)benzyl ether] is prepared from 2-p-hydroxyphenyl-5-n-nonylpyrimidine and p-bromomethyl(2-methylbutyl)benzoate (obtainable from p-bromomethylbenzoic acid and 2-methyl-1-butanol by esterification), mp 29°. The following are prepared analogously:
4-(5-Hexylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxycarbonyl)benzylether]
4-(5-Heptylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxycarbonyl)benzylether]
4-(5-Octylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxycarbonyl)benzylether]
4-(5-Decylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxycarbonyl)benzylether]
4-(5-Pentylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxycarbonyl)benzylether]
4-(5-Butylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxycarbonyl)benzylether]
4-(5-Propylpyrimidin-2-yl)-phenyl-[p-(2-methylbutoxycarbonyl)benzylether]
The following examples concern liquid crystal phases according to the invention:
EXAMPLE A
A liquid crystal phase consisting of
5% of 2-p-cyanophenyl-5-ethyl-1,3-dioxane,
8% of 2-p-cyanophenyl-5-propyl-1,3-dioxane,
8% of 2-p-cyanophenyl-5-butyl-1,3-dioxane,
5% of 2-p-cyanophenyl-5-pentyl-1,3-dioxane,
5% of 4-(5-hexylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether,
12% of 4-(5-hexylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether,
11% of 4-(5-heptylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether,
5% of 4,4'-bis-(trans-4-pentylcyclohexyl)-biphenyl,
11% of trans-1-p-methoxyphenyl-4-propylcyclohexane,
5% of 2-p-methoxyphenyl-5-hexylpyrimidine,
5% of 2-p-pentyloxyphenyl-5-hexylpyrimidine,
5% of 2-p-heptyloxyphenyl-5-hexylpyrimidine,
5% of 2-p-methoxyphenyl-5-heptylpyrimidine,
5% of 2-p-heptyloxyphenyl-5-heptylpyrimidine and
5% of 2-p-nonyloxyphenyl-5-heptylpyrimidine has a melting point of -10° and a clear point of 56°.
EXAMPLE B
A liquid crystal phase consisting of
5% of 2-p-cyanophenyl-5-ethyl-1,3-dioxane,
7% of 2-p-cyanophenyl-5-propyl-1,3-dioxane,
8% of 2-p-cyanophenyl-5-butyl-1,3-dioxane,
7% of 2-p-cyanophenyl-5-pentyl-1,3-dioxane,
5% of 4-(5-hexylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether,
10% of 4-(5-heptylpyrimidin-2-yl)-phenol p-pentylbenzyl ether,
8% of 4-(5-heptylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether,
5% of 4-(trans-4-pentylcyclohexyl)-4'-(trans-4-propylcyclohexyl)-2-fluorobiphenyl,
5% of 4,4'-bis-(trans-4-pentylcyclohexyl)-2-fluorobiphenyl,
10% of trans-1-p-methoxyphenyl-4-propylcyclohexane,
5% of 2-p-methoxyphenyl-5-hexylpyrimidine,
5% of 2-p-pentyloxyphenyl-5-hexylpyrimidine,
5% of 2-p-heptyloxyphenyl-5-hexylpyrimidine,
5% of 2-p-methoxyphenyl-5-heptylpyrimidine,
5% of 2-p-heptyloxyphenyl-5-heptylpyrimidine and
5% of 2-p-nonyloxyphenyl-5-heptylpyrimidine
has a melting point of -14°, a clear point of 65° and a relatively high optical anisotropy.
EXAMPLE C
A liquid crystal phase consisting of
8% of 4-butyl-4'-cyanobiphenyl,
11% of 4-pentyl-4'-cyanobiphenyl,
8% of 4-hexyl-4'-cyanobiphenyl,
5% of 4-(5-hexylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether,
10% of 4-(5-heptylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether,
8% of 4-(5-heptylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether,
5% of 4-(trans-4-pentylcyclohexyl)-4'-(trans-4-propylcyclohexyl)-2-fluorobiphenyl,
5% of 4,4'-bis-(trans-4-pentylcyclohexyl)-2-fluorobiphenyl,
10% of trans-1-p-methoxyphenyl-4-propylcyclohexane,
5% of 2-p-methoxyphenyl-5-hexylpyrimidine,
5% of 2-p-pentyloxyphenyl-5-hexylpyrimidine,
5% of 2-p-heptyloxyphenyl-5-hexylpyrimidine,
5% of 2-p-methoxyphenyl-5-heptylpyrimidine,
5% of 2-p-heptyloxyphenyl-5-heptylpyrimidine and
5% of 2-p-nonyloxyphenyl-5-heptylpyrimidine
has a melting point of -13°, a clear point of 63° and a relatively high optical anistropy.
EXAMPLE D
A liquid crystal phase consisting of
5% of 2-p-cyanophenyl-5-pentylpyrimidine,
10% of 2-p-cyanophenyl-5-heptylpyrimidine,
6% of 2-p-cyanophenyl-5-(p-butylphenyl)-pyrimidine,
6% of 4-(5-hexylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether,
13% of 4-(5-heptylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether,
10% of 4-(5-heptylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether,
5% of 4-(trans-4-pentylcyclohexyl)-4'-(trans-4-propylcyclohexyl)-2-fluorobiphenyl,
5% of 4,4'-bis-(trans-4-pentylcyclohexyl)-2-fluorobiphenyl,
10% of trans-1-p-methoxyphenyl-4-propylcyclohexane,
5% of 2-p-methoxyphenyl-5-hexylpyrimidine,
5% of 2-p-pentyloxyphenyl-5-hexylpyrimidine,
5% of 2-p-heptyloxyphenyl-5-hexylpyrimidine,
5% of 2-p-methoxyphenyl-5-heptylpyrimidine,
5% of 2-p-heptyloxyphenyl-5-heptylpyrimidine and
5% of 2-p-nonyloxyphenyl-5-heptylpyrimidine
has a melting point of -5°, a clear point of 85°, a relatively high optical anisotropy and a particularly low threshold voltage.
EXAMPLE E
A liquid crystal phase is prepared from
17% of p-trans-4-propylcyclohexylbenzonitrile,
23% of p-trans-4-pentylcyclohexylbenzonitrile,
16% of trans-1-p-ethoxyphenyl-4-propylcyclohexane,
14% of trans-1-p-butoxyphenyl-4-propylcyclohexane,
10% of 4-(trans-4-pentylcyclohexyl)-4'-(trans-4-propylcyclohexyl)-biphenyl,
10% of 2-(4-ethoxyphenyl)-5-(trans-4-propylcyclohexyl)pyrimidine and
10% of 4-(5-heptylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether.
EXAMPLE F
A liquid crystal phase is prepared from
21% of p-trans-4-ethylcyclohexylbenzonitrile,
22% of p-trans-4-butylcyclohexylbenzonitrile,
14% of 4-ethyl-4'-cyanobiphenyl,
18% of 4-butyl-4-cyanobiphenyl,
10% of p-pentylphenyl 2-(trans-4-propylcyclohexyl)-pyrimidine-5-carboxylate,
10% of 4-(5-hexylpyrimidin-2-yl)-phenyl p-pentylbenzyl ether and
5% of 4-(5-heptylpyrimidin-2-yl)-phenyl p-hexylbenzyl ether.
The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention do adapt it to various usages and conditions.

Claims (12)

What is claimed is:
1. A pyrimidine compound of the formula
R.sup.1 --Pyr--A.sup.1 --Z.sup.1 --A.sup.2 --R.sup.2
wherein
each of R1 and R2 independently is alkyl of 1 to 12C atoms, or alkyl of 1-12C atoms in which one or two non-adjacent CH2 groups are replaced by --O--, --CO--, --O--CO-- or --CO--O-- and one of R1 and R2 can also be H, F, Cl or Br, Pyr is pyrimidine-2,5-diyl, A1 is 1,4-cyclohexylene (Cy) or 1,4-phenylene (Phe), A2 is 1,4-phenylene, and Z1 is --CH2 CH2 --, --CH2 O-- or --OCH2 --.
2. A compound of claim 1 of the formula
R1 --Pyr--Phe--OCH2 --Phe--R2,
R1 --Pyr--Phe--CH2 CH2 --Phe--R2, or
R1 --Pyr--Phe--CH2 O--Phe--R2.
3. A compound of claim 1 of the formula
R1 --Pyr--Cy--OCH2 --Phe--R2,
R1 --Pyr--Cy--CH2 CH2 --Phe--R2, or
R1 --Pyr--Cy--CH2 O--Phe--R2.
4. A compound of claim 1 wherein R1 and R2 are alkyl, alkoxy or oxaalkyl.
5. A compound of claim 1 wherein Z1 is --CH2 --CH2 --.
6. A compound of claim 4 wherein Z1 is --CH2 --O-- or --O--CH2 --.
7. A compound of claim 1 wherein Z1 is --OCH2 --.
8. A compound of claim 1 of the formula
Alkyl--Pyr--Phe--OCH2 --Phe--alkyl or
Alkyl--Pyr--Phe--OCH2 --Phe--alkoxy.
9. A compound of claim 4 wherein R1 or R2 has an optically active C-atom.
10. In a liquid crystal phase comprising at least two liquid crystal components, the improvement wherein at least one component is a compound of claim 1.
11. In a liquid crystal display element, comprising a liquid crystal phase, the improvement wherein the phase is of claim 10.
12. In an electro-optical display element comprising a liquid crystalline dielectric, the improvement wherein the dielectric is a phase of claim 10.
US06/832,120 1985-02-23 1986-02-24 Pyrimidine derivatives Expired - Fee Related US4776973A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3506446 1985-02-23
DE19853506446 DE3506446A1 (en) 1985-02-23 1985-02-23 PYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
US4776973A true US4776973A (en) 1988-10-11

Family

ID=6263416

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/832,120 Expired - Fee Related US4776973A (en) 1985-02-23 1986-02-24 Pyrimidine derivatives

Country Status (6)

Country Link
US (1) US4776973A (en)
EP (1) EP0199004B1 (en)
JP (1) JPS61210074A (en)
KR (1) KR860006446A (en)
DD (1) DD243290A5 (en)
DE (2) DE3506446A1 (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877547A (en) * 1986-02-26 1989-10-31 Merck Patent Gesellschaft Mit Beschrankter Haftung Liquid crystal display element
US4882082A (en) * 1984-02-07 1989-11-21 Merck Patent Gesellschaft Mit Beschrankter Haftung Nitrogen-containing hetercyclic compounds
US4886620A (en) * 1985-09-18 1989-12-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Smectic liquid-crystalline phases
US4891151A (en) * 1987-09-19 1990-01-02 Hoechst Aktiengesellschaft Liquid-crystalline phenylpyrimidinyl cyclohexanecarboxylates having a smectic phase, a process for their preparation, and their use in liquid-crystal mixtures
US4906752A (en) * 1987-03-24 1990-03-06 Hoechst Aktiengesellschaft Liquid-crystal 5-phenylpyrimidine derivatives having sc or sc* phases and a process for preparing them
US4906401A (en) * 1987-03-24 1990-03-06 Hoechst Aktiengesellschaft Use of liquid-crystal 5-phenylpyrimidine derivatives as components of smectic liquid-crystal mixtures
US4913532A (en) * 1987-10-19 1990-04-03 Casio Computer Co., Ltd. Liquid crystal composition and liquid crystal display device using the same
US4913837A (en) * 1986-01-03 1990-04-03 Merck Patent Gesellschaft Mit Beschrankter Haftung Heterocyclic compounds
US4913838A (en) * 1987-03-20 1990-04-03 Chisso Corporation Liquid crystal compound with a 4-(optically active alkyl)-3-cyanophenyl group
US4913530A (en) * 1987-11-10 1990-04-03 Sharp Kabushiki Kaisha Liquid crystal display
US4918213A (en) * 1987-07-28 1990-04-17 Canon Kabushiki Kaisha Optically active compound and liquid crystal composition containing same
US4925590A (en) * 1988-03-10 1990-05-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Derivatives of 4-cyano-2,3-difluorophenol
US5002694A (en) * 1985-09-18 1991-03-26 Merck Patent Gesellschaft Mit Beschrankter Haftung Nitrogen-containing heterocyclic compounds
US5013476A (en) * 1986-11-20 1991-05-07 Hoffmann-La Roche Inc. Liquid crystal compounds and indicating device employing same
US5064566A (en) * 1985-04-27 1991-11-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Smectic liquid crystal phases
US5128061A (en) * 1990-08-14 1992-07-07 Optical Shields, Inc. Phenyl-pyrimidine liquid crystal materials
US5178790A (en) * 1988-03-10 1993-01-12 Merck Patent Gesellschaft Mit Beschraenkter Haftung Supertwist liquid crystal display
US5198149A (en) * 1988-03-10 1993-03-30 Merck Patent Gesellschaft Mit Beschrankter Haftung Smectic liquid-crystal medium
US5204019A (en) * 1988-03-10 1993-04-20 Merck Patent Gesellschaft Mit Beschrankter Haftung 2,3-difluorobiphenyls
US5209866A (en) * 1988-03-10 1993-05-11 Merck Patent Gesellschaft Mit Beschrankter Haftung Heterocyclic 1,2-difluorobenzene derivatives
US5211878A (en) * 1988-03-10 1993-05-18 Merck Patent Gesellschaft Mit Beschrankter Haftung Difluorobenzonitrile derivatives
US5230827A (en) * 1988-03-10 1993-07-27 Merck Patent Gesellschaft Mit Beschrankter Haftung Derivatives of 2,3-difluorobenzoic acid
US5230826A (en) * 1987-11-06 1993-07-27 Hoffmann-La Roche Inc. Halobenzene liquid crystals
US5232624A (en) * 1988-03-10 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung Chiral 1,2-difluorobenzene derivatives
US5236620A (en) * 1988-03-10 1993-08-17 Merck Patent Gesellschaft Mit Beschrankter Haftung 2,3-difluorobenzene derivatives
US5248447A (en) * 1988-03-10 1993-09-28 Merck Patent Gesellschaft Mit Beschrankter Haftung 2,3-difluorohydroquinone derivatives
US5273680A (en) * 1988-03-10 1993-12-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Fluorinated oligophenyls and their use in liquid crystal materials
US5279762A (en) * 1985-04-27 1994-01-18 Merck Patent Gesellschaft Mit Beschrankter Haftung Smectic liquid crystal phases
US5279764A (en) * 1988-03-10 1994-01-18 Merck Patent Gesellschaft Mit Beschrankter Haftung Dihalogenobenzene derivatives
US5424004A (en) * 1990-05-09 1995-06-13 Canon Kabushiki Kaisha Chiral smectic liquid crystal composition, liquid crystal device, display apparatus and display method
US5512208A (en) * 1988-07-14 1996-04-30 Canon Kabushiki Kaisha Ferroelectric chiral smectic liquid crystal composition and liquid crystal device using same
US5589103A (en) * 1993-01-08 1996-12-31 Canon Kabushiki Kaisha Mesomorphic compound, liquid crystal composition containing same, and liquid crystal device using same

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3510432A1 (en) * 1985-03-22 1986-09-25 Merck Patent Gmbh, 6100 Darmstadt CYCLOHEXANDERIVATE
DE3515373A1 (en) * 1985-04-27 1986-11-06 Merck Patent Gmbh, 6100 Darmstadt NITROGENIC HETEROCYCLES
DE3515633A1 (en) * 1985-05-02 1986-11-06 Merck Patent Gmbh, 6100 Darmstadt BENZONITRILE
DE3518734A1 (en) * 1985-05-24 1986-11-27 Merck Patent Gmbh, 6100 Darmstadt Smectic liquid crystal phases
US4933955A (en) * 1988-02-26 1990-06-12 Silicon General, Inc. Timing generator
ES2040936T3 (en) * 1988-07-13 1993-11-01 Canon Kabushiki Kaisha ESMETIC CHIRAL FERROELECTRIC LIQUID CRYSTAL COMPOSITION AND A LIQUID CRYSTAL DEVICE USING THE LIQUID CRYSTAL COMPOSITION.
EP0350893B1 (en) * 1988-07-13 1994-02-02 Canon Kabushiki Kaisha Ferroelectric chiral smectic liquid crystal composition and liquid crystal device using same
US5186858A (en) * 1988-07-13 1993-02-16 Canon Kabushiki Kaisha Ferroelectric chiral smectic liquid crystal composition and liquid crystal device using same
DE4002609A1 (en) * 1989-09-07 1991-03-21 Merck Patent Gmbh New di:fluoro-benzonitrile cpds. contg. pyrimidin-di:yl gp. - used in liquid crystal medium esp. for electro=optical display with good low temp. properties

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311610A (en) * 1979-08-20 1982-01-19 Veb Werk Fur Fernsehelektronik Im Veb Kombinat Mikroelektronik Liquid crystalline 5-alkyl-2 (4-acyloxy-phenyl)-pyrimidine
EP0056501A2 (en) * 1981-01-19 1982-07-28 MERCK PATENT GmbH Liquid crystal mixture
GB2092169A (en) * 1980-12-16 1982-08-11 Brown Boveri Bbc & Co Ltd Liquid crystal mixtures comprising weakly polar non-cyano components and strongly polar cyano components
EP0084194A1 (en) * 1982-01-14 1983-07-27 MERCK PATENT GmbH Liquid crystal mixtures
US4512636A (en) * 1982-06-15 1985-04-23 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdon Of Great Britian And Northern Ireland Of Whitehall Liquid crystal compounds
US4528114A (en) * 1981-12-18 1985-07-09 Hoffmann-La Roche Inc. Acetylenes
EP0149238A2 (en) * 1984-01-17 1985-07-24 MERCK PATENT GmbH Nitrogen containing heterocycles
DE3404116A1 (en) * 1984-02-07 1985-08-08 Merck Patent Gmbh, 6100 Darmstadt NITROGENIC HETEROCYCLES
DE3411571A1 (en) * 1984-03-29 1985-10-10 Merck Patent Gmbh, 6100 Darmstadt PYRIMIDINE
WO1986000067A1 (en) * 1984-06-13 1986-01-03 The Secretary Of State For Defence In Her Britanni Pyrimidines
US4564694A (en) * 1981-02-25 1986-01-14 Hitachi, Ltd. Colorless liquid crystalline compounds
DE3500909A1 (en) * 1985-01-12 1986-07-17 Merck Patent Gmbh, 6100 Darmstadt PYRIMIDINE
US4621901A (en) * 1984-07-12 1986-11-11 Hoffmann-La Roche Inc. Novel liquid crystal mixtures
US4623477A (en) * 1983-10-07 1986-11-18 Chisso Corporation Ester compounds having a pyrimidine ring
US4632515A (en) * 1984-01-11 1986-12-30 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Heterocyclically substituted ethanes and their use in liquid crystal materials and devices
US4659502A (en) * 1984-01-17 1987-04-21 Merck Patent Gesellschaft Mit Beschrankter Haftung Ethane derivatives
US4676604A (en) * 1983-03-16 1987-06-30 Hoffmann-La Roche Inc. Liquid crystals
US4723005A (en) * 1983-09-10 1988-02-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Anisotropic compounds and liquid crystal mixtures

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939876A (en) * 1982-08-26 1984-03-05 Chisso Corp Pyrimidine derivative

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311610A (en) * 1979-08-20 1982-01-19 Veb Werk Fur Fernsehelektronik Im Veb Kombinat Mikroelektronik Liquid crystalline 5-alkyl-2 (4-acyloxy-phenyl)-pyrimidine
GB2092169A (en) * 1980-12-16 1982-08-11 Brown Boveri Bbc & Co Ltd Liquid crystal mixtures comprising weakly polar non-cyano components and strongly polar cyano components
EP0056501A2 (en) * 1981-01-19 1982-07-28 MERCK PATENT GmbH Liquid crystal mixture
US4564694A (en) * 1981-02-25 1986-01-14 Hitachi, Ltd. Colorless liquid crystalline compounds
US4528114A (en) * 1981-12-18 1985-07-09 Hoffmann-La Roche Inc. Acetylenes
EP0084194A1 (en) * 1982-01-14 1983-07-27 MERCK PATENT GmbH Liquid crystal mixtures
US4512636A (en) * 1982-06-15 1985-04-23 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdon Of Great Britian And Northern Ireland Of Whitehall Liquid crystal compounds
US4630897A (en) * 1982-06-15 1986-12-23 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Liquid crystal compounds
US4676604A (en) * 1983-03-16 1987-06-30 Hoffmann-La Roche Inc. Liquid crystals
US4723005A (en) * 1983-09-10 1988-02-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Anisotropic compounds and liquid crystal mixtures
US4623477A (en) * 1983-10-07 1986-11-18 Chisso Corporation Ester compounds having a pyrimidine ring
US4632515A (en) * 1984-01-11 1986-12-30 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Heterocyclically substituted ethanes and their use in liquid crystal materials and devices
US4659502A (en) * 1984-01-17 1987-04-21 Merck Patent Gesellschaft Mit Beschrankter Haftung Ethane derivatives
EP0149238A2 (en) * 1984-01-17 1985-07-24 MERCK PATENT GmbH Nitrogen containing heterocycles
US4713197A (en) * 1984-01-17 1987-12-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Nitrogen-containing heterocyclic compounds
DE3404116A1 (en) * 1984-02-07 1985-08-08 Merck Patent Gmbh, 6100 Darmstadt NITROGENIC HETEROCYCLES
DE3411571A1 (en) * 1984-03-29 1985-10-10 Merck Patent Gmbh, 6100 Darmstadt PYRIMIDINE
WO1986000067A1 (en) * 1984-06-13 1986-01-03 The Secretary Of State For Defence In Her Britanni Pyrimidines
US4621901A (en) * 1984-07-12 1986-11-11 Hoffmann-La Roche Inc. Novel liquid crystal mixtures
DE3500909A1 (en) * 1985-01-12 1986-07-17 Merck Patent Gmbh, 6100 Darmstadt PYRIMIDINE

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882082A (en) * 1984-02-07 1989-11-21 Merck Patent Gesellschaft Mit Beschrankter Haftung Nitrogen-containing hetercyclic compounds
US5279762A (en) * 1985-04-27 1994-01-18 Merck Patent Gesellschaft Mit Beschrankter Haftung Smectic liquid crystal phases
US5064566A (en) * 1985-04-27 1991-11-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Smectic liquid crystal phases
US5002694A (en) * 1985-09-18 1991-03-26 Merck Patent Gesellschaft Mit Beschrankter Haftung Nitrogen-containing heterocyclic compounds
US4886620A (en) * 1985-09-18 1989-12-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Smectic liquid-crystalline phases
US4913837A (en) * 1986-01-03 1990-04-03 Merck Patent Gesellschaft Mit Beschrankter Haftung Heterocyclic compounds
US4877547A (en) * 1986-02-26 1989-10-31 Merck Patent Gesellschaft Mit Beschrankter Haftung Liquid crystal display element
US5013476A (en) * 1986-11-20 1991-05-07 Hoffmann-La Roche Inc. Liquid crystal compounds and indicating device employing same
US4913838A (en) * 1987-03-20 1990-04-03 Chisso Corporation Liquid crystal compound with a 4-(optically active alkyl)-3-cyanophenyl group
US4906401A (en) * 1987-03-24 1990-03-06 Hoechst Aktiengesellschaft Use of liquid-crystal 5-phenylpyrimidine derivatives as components of smectic liquid-crystal mixtures
US4906752A (en) * 1987-03-24 1990-03-06 Hoechst Aktiengesellschaft Liquid-crystal 5-phenylpyrimidine derivatives having sc or sc* phases and a process for preparing them
US4918213A (en) * 1987-07-28 1990-04-17 Canon Kabushiki Kaisha Optically active compound and liquid crystal composition containing same
US4891151A (en) * 1987-09-19 1990-01-02 Hoechst Aktiengesellschaft Liquid-crystalline phenylpyrimidinyl cyclohexanecarboxylates having a smectic phase, a process for their preparation, and their use in liquid-crystal mixtures
US4913532A (en) * 1987-10-19 1990-04-03 Casio Computer Co., Ltd. Liquid crystal composition and liquid crystal display device using the same
US5454974A (en) * 1987-11-06 1995-10-03 Hoffmann-La Roche Inc. Halobenzene liquid crystals
US5230826A (en) * 1987-11-06 1993-07-27 Hoffmann-La Roche Inc. Halobenzene liquid crystals
US5302317A (en) * 1987-11-06 1994-04-12 Hoffmann-La Roche Inc. Halobenzene liquid crystals
US4913530A (en) * 1987-11-10 1990-04-03 Sharp Kabushiki Kaisha Liquid crystal display
US5178790A (en) * 1988-03-10 1993-01-12 Merck Patent Gesellschaft Mit Beschraenkter Haftung Supertwist liquid crystal display
US5248447A (en) * 1988-03-10 1993-09-28 Merck Patent Gesellschaft Mit Beschrankter Haftung 2,3-difluorohydroquinone derivatives
US5211878A (en) * 1988-03-10 1993-05-18 Merck Patent Gesellschaft Mit Beschrankter Haftung Difluorobenzonitrile derivatives
US5230827A (en) * 1988-03-10 1993-07-27 Merck Patent Gesellschaft Mit Beschrankter Haftung Derivatives of 2,3-difluorobenzoic acid
US5204019A (en) * 1988-03-10 1993-04-20 Merck Patent Gesellschaft Mit Beschrankter Haftung 2,3-difluorobiphenyls
US5232624A (en) * 1988-03-10 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung Chiral 1,2-difluorobenzene derivatives
US5236620A (en) * 1988-03-10 1993-08-17 Merck Patent Gesellschaft Mit Beschrankter Haftung 2,3-difluorobenzene derivatives
US5209866A (en) * 1988-03-10 1993-05-11 Merck Patent Gesellschaft Mit Beschrankter Haftung Heterocyclic 1,2-difluorobenzene derivatives
US5273680A (en) * 1988-03-10 1993-12-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Fluorinated oligophenyls and their use in liquid crystal materials
US5198149A (en) * 1988-03-10 1993-03-30 Merck Patent Gesellschaft Mit Beschrankter Haftung Smectic liquid-crystal medium
US5279764A (en) * 1988-03-10 1994-01-18 Merck Patent Gesellschaft Mit Beschrankter Haftung Dihalogenobenzene derivatives
US4925590A (en) * 1988-03-10 1990-05-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Derivatives of 4-cyano-2,3-difluorophenol
US5512208A (en) * 1988-07-14 1996-04-30 Canon Kabushiki Kaisha Ferroelectric chiral smectic liquid crystal composition and liquid crystal device using same
US5424004A (en) * 1990-05-09 1995-06-13 Canon Kabushiki Kaisha Chiral smectic liquid crystal composition, liquid crystal device, display apparatus and display method
US5128061A (en) * 1990-08-14 1992-07-07 Optical Shields, Inc. Phenyl-pyrimidine liquid crystal materials
US5589103A (en) * 1993-01-08 1996-12-31 Canon Kabushiki Kaisha Mesomorphic compound, liquid crystal composition containing same, and liquid crystal device using same

Also Published As

Publication number Publication date
EP0199004A1 (en) 1986-10-29
EP0199004B1 (en) 1989-09-06
DE3665456D1 (en) 1989-10-12
DE3506446A1 (en) 1986-08-28
KR860006446A (en) 1986-09-11
JPS61210074A (en) 1986-09-18
DD243290A5 (en) 1987-02-25

Similar Documents

Publication Publication Date Title
US4776973A (en) Pyrimidine derivatives
US4882082A (en) Nitrogen-containing hetercyclic compounds
US4713197A (en) Nitrogen-containing heterocyclic compounds
US4622164A (en) Bicyclohexyls
US4818431A (en) Liquid crystal dielectric
US4943384A (en) Cyclohexane derivatives
US4846998A (en) Cyclohexane derivatives
US4510069A (en) Cyclohexane derivatives
US4704227A (en) Liquid crystal compounds
US5064569A (en) Optically active compounds
US4724097A (en) Bicyclohexylethanes
US4627933A (en) Liquid crystalline phases containing alkylene-type bridges
JP2632401B2 (en) Substituted phenyl trifluoromethyl ether compounds
US4620938A (en) Hydroterphenyls
US5043093A (en) Pyrimidines
US5055223A (en) Aryl-sulfur pentafluorides
US4913837A (en) Heterocyclic compounds
US5324449A (en) Substituted phenyl trifluoromethyl ethers
WO1987004426A2 (en) Vinyl compositions
JPH024756A (en) 4-cyano-2, 3-difluorophenol derivative
US4707295A (en) Bicyclooctane derivatives
US4986931A (en) Cyclohexane derivatives
US4871470A (en) Cyclohexane derivatives
EP0445257B1 (en) Pyridine derivatives and a liquid crystal medium
US4659503A (en) Pyridylthiophenes

Legal Events

Date Code Title Description
AS Assignment

Owner name: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:BOFINGER, KLAUS;ROMER, MICHAEL;SCHEUBLE, BERNHARD;AND OTHERS;REEL/FRAME:004888/0445

Effective date: 19860212

Owner name: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOFINGER, KLAUS;ROMER, MICHAEL;SCHEUBLE, BERNHARD;AND OTHERS;REEL/FRAME:004888/0445

Effective date: 19860212

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19961016

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362